Shane Albright

Shane Albright

Shane Albright
Silicon Valley
+1 650 752 3219

Shane Albright is a partner in the firm’s Life Sciences group. Mr. Albright represents life science and technology companies in a wide range of corporate, financial and commercial matters, with a particular emphasis on complex transactions involving intellectual property. He has extensive experience counseling clients on corporate partnering issues, strategic alliances, technology licenses and key commercial contracts, such as manufacturing and distribution agreements.

Mr. Albright regularly provides advice on licensing and commercial contract issues in connection with mergers and acquisitions, IPOs and other public financings. He also represents emerging growth companies and their investors in venture financings, other funding transactions and general corporate matters. Mr. Albright’s clients include companies in the biopharmaceutical, medical device, diagnostics, hardware, software, medical instrumentation, digital health, vaccine and research reagent spaces, as well as entities that fund or conduct medical research.

Prior to joining Goodwin in 2018, Mr. Albright was a partner at DLA Piper.


Mr. Albright’s representative matters include:

  • A public pharmaceutical company in the negotiation of a series of territory-specific out-licenses for its erectile dysfunction drug*
  • A medical-device manufacturer in a collaboration agreement with a pharmaceutical company under which the parties will develop and commercialize new medicines based on the combination of the pharmaceutical company’s drugs with devices developed by the client*
  • A venture-backed company in a multimillion-dollar collaboration with a pharmaceutical company for development of an oral treatment for psoriasis*
  • A San Francisco-based research institute in multiple licenses and/or research collaborations with leading global pharmaceutical companies*
  • A biopharmaceutical company that focuses on creating treatments for rare diseases in its acquisition of worldwide rights to two drugs used in treating urea-cycle disorders*
  • Negotiated and drafted multiple agreements on behalf of a biomedical research consortium in connection with the launch of a ground-breaking multi-drug clinical trial*
  • A U.S. biotechnology company in the exclusive out-licensing of Japanese development and commercialization rights to the company’s oncology drug*
  • Assisted a U.S. biotechnology company in the formation of a global partnership with a pharmaceutical company focusing on the development and commercialization of the client’s DNA-based therapeutics*
  • Advised a startup biotechnology company in the outsourcing of research and development activities to an ex-U.S. research institute*
  • Advised a public life science company on the formation of a strategic alliance with a U.S. university*

* Denotes experience prior to joining Goodwin.




Stanford Law School

(with distinction)

Doctor of PhilosophyMolecular and Cell Biology1999

University of California, Berkeley

BSBiological Sciences1991

Stanford University

(with distinction)



  • California

Recognition & Awards

In recognition of his outstanding transactional work, Mr. Albright has been featured as a “Life Sciences Star” in LMG Life Sciences.


Mr. Albright is a frequent speaker on issues relating to licensing and corporate partnering.